Judge Upheld Novartis Patent Filing for Entresto
The ruling protects pharmaceutical patent listing practices, clarifying how drug makers can defend market exclusivity.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Should pharmaceutical companies face legal penalties for strategies that delay generic drug entry?
A federal judge dismissed a class action lawsuit alleging Novartis improperly listed a patent in the FDA Orange Book to delay generic competition for its drug Entresto. The decision supports current pharmaceutical patent listing procedures for companies operating in the U.S. market.
Why it matters
The ruling clarifies legal boundaries for drug manufacturers using FDA patent listings to manage market exclusivity. For operators in the life sciences sector, the outcome provides a precedent on how patent disclosures influence generic entry timelines and competitive dynamics.
Novartis earned over $2 billion in U.S. sales during the six-month delay alleged by plaintiffs. In 2025, Entresto accounted for 14% of the company's total sales, though quarterly revenue fell 42% to $1.31 billion in Q1 2026.
The players
Novartis
A global pharmaceutical company headquartered in Switzerland with a significant portfolio of patented cardiovascular drugs.
Lewis Liman
A U.S. District Judge in Manhattan who presided over the litigation regarding FDA patent listing requirements.
Iron Workers Local 580 Insurance Fund
A benefit fund that acts as a drug purchaser and filed the class action lawsuit against Novartis.
The details
The court examined whether the disputed patent adequately covered the specific combined form of Entresto or merely its base components. Judge Lewis Liman determined the listing in the FDA Orange Book was legitimate under current regulatory standards. This effectively shielded Novartis from claims that it artificially maintained market exclusivity at the expense of generic competitors.
Timeline
The Iron Workers Local 580 Insurance Fund filed the lawsuit in 2025.
Entresto sales declined 42% to $1.31 billion during Q1 2026.
Judge Liman dismissed the lawsuit on September 23, 2026.
Market Landscape
This ruling maintains the established regulatory framework governing how pharmaceutical companies use the FDA Orange Book to secure intellectual property protections. It follows a pattern of litigation regarding whether patent listings are used to appropriately cover product innovations or to block generic entry.
Operators in the pharmaceutical and healthcare supply chain should monitor future court interpretations of patent listings, as these decisions impact the timing of generic product availability. Compliance officers should ensure that patent filing strategies remain aligned with the legal precedents set by this district court ruling.
The takeaway
The court's decision provides clarity on the validity of patent listings within the FDA Orange Book framework. Leaders in the space should continue to track how patent listing disclosures are challenged in future litigation, as these legal outcomes directly influence generic market entry dates.
Further reading
For more on industry regulatory standards, visit the Healthcare section.
Live Poll
Should pharmaceutical companies face legal penalties for strategies that delay generic drug entry?
